Tag Archive for: biotech

ImaginAb Launches Phase II C-IT Neo Trial using CD8+ Cell Imaging to Investigate Neoadjuvant Immunotherapy

/in

Los Angeles, USA and New York, USA, December 14, 2022 – ImaginAb Inc., a global biotechnology company focused on developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent and radiopharmaceutical therapy (RPT) products, in collaboration with Memorial Sloan Kettering Cancer Center (MSK) and Melanoma Research Alliance (MRA), has launched an investigator-initiated Phase II trial to explore the […]

Read more

LSX and Jefferies – Insights from the busiest week in European biotech 

/in ,

The LSX Inv€$tival Showcase kicked off a hectic week in life sciences on 15 November, with these two key events in the biotech calendar making one of the busiest weeks of the year.  Investors and biotechs saw this as a vital chance to meet up and discuss strategies and potential deals amid these dicey market […]

Read more

NXI Therapeutics Expands Management Team and Board Ahead of Next Growth Stage

/in

Experienced life sciences executive Dr Ruben Herrendorff appointed as CEO Serial biotech entrepreneur Dr Ulf Grawunder appointed as Board member Targeted therapy aims to treat autoimmune disease whilst avoiding serious, long-term complications of the current non-selective immunosuppression 30 November 2022, Basel, Switzerland – NXI Therapeutics[1], the specialist biotech developing next generation immunosuppressive drugs for autoimmune […]

Read more

Panel Summaries from Optimum’s 14th Annual Healthcare Investor Conference 2022

/in ,

For those that were unable to attend on Optimum’s 14th Annual Healthcare Investor Conference, or indeed would like a recap of what was shared on the day, we have been releasing the top takeaways from the panels!   Our first panel of the day, chaired by Stephen Hansen, from BioCentury, saw a panel of blue chip […]

Read more

STORM Therapeutics doses first patient with oral METTL3 targeting drug candidate in a solid tumor Phase 1 study

/in

23 November 2022, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, today announces that the first patient has been dosed with STC-15, the Company’s first-in-class clinical candidate. Read more…

Read more
© Optimum Strategic Communications.